Scarica l'app Stockscreener
0.828
0.24%
-0.002
Precedente Chiudi:
$0.83
Aprire:
$0.83
Volume 24 ore:
155.93K
Relative Volume:
0.03
Capitalizzazione di mercato:
$3.02M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0299
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
-2.84%
1M Prestazione:
-26.73%
6M Prestazione:
+74.28%
1 anno Prestazione:
-80.74%
Intervallo 1D:
$0.803
$0.8699
Intervallo di 1 settimana:
$0.803
$0.9521
Portata 52W:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Confronta WINT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.828 | 3.03M | 0 | -11.38M | -12.72M | -27.73 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Windtree Therapeutics Inc. Reports Q1 2025 Financial Results - TipRanks
Windtree Therapeutics (WINT) Registers Up to 42.17M Shares for R - GuruFocus
Windtree Therapeutics (WINT) Plans to Sell Over 42 Million Shares | WINT Stock News - GuruFocus
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime - MSN
Windtree (WINT) Sets Ambitious Plans for Revenue Growth and Rese - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Resul - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates | WINT Stock News - GuruFocus
Windtree Therapeutics Transforms Business Model: New Revenue Strategy, Real Estate Deal, and Clinical Progress - Stock Titan
WINDTREE THERAPEUTICS INC /DE/ SEC 10-Q Report - TradingView
Windtree Therapeutics (WINT) to Release Earnings on Wednesday - Defense World
WINT: Windtree Therapeutics Reveals Promising Data on Istaroxime - GuruFocus
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - The Manila Times
Windtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure Congress - Nasdaq
Windtree Therapeutics Announces Plans to Acquire Multifamily Residential Property - MSN
Warrington-Based Windtree Therapeutics Buys Huston Apartment Complex - BUCKSCO.Today
Daily Progress: Windtree Therapeutics Inc (WINT) Drop -11.76, Closing at 0.90 - DWinneX
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics (WINT) Eyes U.S. Exclusivity for Istaroxime | WINT Stock News - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Prope - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - The Manila Times
Windtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic Shock - Nasdaq
Windtree Secures 7.5-Year Exclusivity Strategy for Revolutionary Cardiogenic Shock Treatment - Stock Titan
Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex - The Business Journals
WINT’s Stock Market Adventure: -94.27% YTD Growth Amidst Volatility - investchronicle.com
Examining Windtree Therapeutics Inc (WINT) more closely is necessary - uspostnews.com
Market Resilience: Windtree Therapeutics Inc (WINT) Finishes Weak at 1.00, Down -14.53 - DWinneX
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acqui - GuruFocus
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acquisition | WINT Stock News - GuruFocus
Windtree Therapeutics Raises $2.5M in Private Placement - TipRanks
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development - The Manila Times
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Evofem Biosciences Inks Amendment with Windtree for PHEXXI Supply - Investing.com
Windtree Therapeutics Delays Annual Report Filing - TipRanks
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):